{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:14:08Z","timestamp":1746677648563,"version":"3.40.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) is an immune-mediated polyradiculoneuropathy that remains a debilitating disease despite medical treatment. Numerous challenges still exist, including the development of disease-modifying therapies that can improve prognosis, particularly in patients with poor prognostic outcomes. In this study, we explored clinical trials related to GBS, analyzed the trial characteristics, suggested some ideas for improvement, and discussed recent advances.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>On December 30, 2021, the authors searched ClinicalTrials.gov for all interventional and therapeutic clinical trials related to GBS, without any restrictions on the date or location. Trial characteristics including trial duration, location, phase, sample size, and publications were retrieved and analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-one trials fulfilled the selection criteria. Clinical trials were conducted in 11 different countries, most of them occurring in Asia. On average, the trial duration across the phases was around 2 years. About two-thirds of trials were completed, and 39% of trials were in the early phases (1 and 2). Only 24% of all trials and 60% of completed trials have publications in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The study revealed a low number of trials, lack of geographic diversity, scanty enrollment of patients, and paucity of clinical trial duration and publications regarding GBS clinical trials. Optimization of GBS trials is fundamental to achieving effective therapies for this disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000441","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T16:34:45Z","timestamp":1676997285000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Landscape of Guillain\u2013Barr\u00e9 Syndrome Interventional Clinical Trials"],"prefix":"10.1097","volume":"24","author":[{"given":"Mustafa","family":"Saleh","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Lebanon;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Boukhdoud","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Lebanon;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayam","family":"Boukhdoud","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Lebanon;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Al Zein","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Lebanon;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Lebanon;"},{"name":"School of Medicine, Lebanese American University, Byblos, Lebanon;"},{"name":"Institut National de Sant\u00e9 Publique, Epid\u00e9miologie Clinique et Toxicologie (INSPECT-LB), Beirut, Lebanon; and"},{"name":"University of Nicosia Medical School, Nicosia, Cyprus."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250507","first-page":"565","article-title":"Criteria for diagnosis of Guillain-Barr\u00e9 syndrome","volume":"3","year":"1978","journal-title":"Ann Neurol."},{"issue":"suppl l","key":"R2-20250507","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol."},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1734-1140(10)70261-9","article-title":"Guillain-Barr\u00e9 syndrome (GBS)","volume":"62","author":"Pithadia","year":"2010","journal-title":"Pharmacol Rep."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"R5-20250507","first-page":"1295","article-title":"Guillain-Barr\u00e9 syndrome","volume":"23","author":"Donofrio","year":"2017","journal-title":"Continuum (Minneap Minn)"},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"R7-20250507","first-page":"357","article-title":"Guillain-Barre syndrome: etiology and pathogenesis","volume":"54","author":"Avila-Funes","year":"2002","journal-title":"Rev Invest Clin."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11882-011-0190-y","article-title":"Guillain-Barr\u00e9 syndrome: modern theories of etiology","volume":"11","author":"Hardy","year":"2011","journal-title":"Curr Allergy Asthma Rep."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/504294","article-title":"Incidence of Guillain-Barr\u00e9 syndrome among patients with campylobacter infection: a general practice research database study","volume":"194","author":"Tam","year":"2006","journal-title":"J Infect Dis."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/glycob\/cwp027","article-title":"Antiganglioside antibodies and their pathophysiological effects on Guillain\u2013Barr\u00e9 syndrome and related disorders\u2014a review","volume":"19","author":"Kaida","year":"2009","journal-title":"Glycobiology"},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain\u2013barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"New Engl J Med."},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1085-9489.2005.0010203.x","article-title":"Treatment of Guillain-Barre syndrome and CIDP","volume":"10","author":"van Doorn","year":"2005","journal-title":"J Peripher Nerv Syst."},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12016-013-8388-5","article-title":"New strategies in the management of Guillain\u2013Barr\u00e9 syndrome","volume":"47","author":"Xiao","year":"2014","journal-title":"Clinic Rev Allerg Immunol."},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1007\/s00415-006-5001-3","article-title":"Epidemiology of neuroimmunological diseases","volume":"253","author":"Flachenecker","year":"2006","journal-title":"J Neurol."},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3389\/fnins.2020.00633","article-title":"Fulminant Guillain\u2013Barr\u00e9 syndrome and spontaneous intraventricular hemorrhage: a case report and literature review","volume":"14","author":"Hu","year":"2020","journal-title":"Front Neurosci."},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14728214.2011.531699","article-title":"Emerging drugs for Guillain-Barr\u00e9 syndrome","volume":"16","author":"Walgaard","year":"2011","journal-title":"Expert Opin Emerging Drugs"},{"key":"R19-20250507","first-page":"7614","article-title":"Guillain-Barr\u00e9 syndrome: report of two rare clinical cases occurring after allergenic bone grafting in oral maxillofacial surgery","volume":"8","author":"Cicci\u00f9","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"226572","DOI":"10.1136\/bcr-2018-226572","article-title":"A rare case of recurrent Guillain-Barr\u00e9 syndrome without albuminocytological dissociation","volume":"2018","author":"Yelam","year":"2018","journal-title":"BMJ Case Rep."},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/jnnp-2013-306212","article-title":"Guillain-barre syndrome in Asia","volume":"85","author":"Bae","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41582-021-00467-y","article-title":"Guillain\u2013Barr\u00e9 syndrome in low-income and middle-income countries: challenges and prospects","volume":"17","author":"Papri","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro-Oncology"},{"key":"R24-20250507","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12874-020-00949-5","article-title":"Factors associated with patient willingness to participate in anaesthesia clinical trials: a vignette-based cross-sectional study","volume":"20","author":"Noirmain","year":"2020","journal-title":"BMC Med Res Methodol."},{"key":"R25-20250507","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun."},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13063-020-4079-8","article-title":"Streamlining and cycle time reduction of the startup phase of clinical trials","volume":"21","author":"Abu-Shaheen","year":"2020","journal-title":"Trials"},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S1470-2045(19)30271-2","article-title":"Master protocols in clinical trials: a universal Swiss Army knife?","volume":"20","author":"Sudhop","year":"2019","journal-title":"Lancet Oncol."},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12029-020-00411-1","article-title":"Targeted therapies in trial for non-resectable gallbladder cancer","volume":"52","author":"Nasrallah","year":"2021","journal-title":"J Gastrointest Canc"},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.2014.10716","article-title":"Sharing and reporting the results of clinical trials","volume":"313","author":"Hudson","year":"2015","journal-title":"JAMA"},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit Care"},{"key":"R31-20250507","doi-asserted-by":"crossref","first-page":"e022862","DOI":"10.1136\/bmjopen-2018-022862","article-title":"Small volume plasma exchange for Guillain-Barr\u00e9 syndrome in resource-limited settings: a phase II safety and feasibility study","volume":"8","author":"Islam","year":"2018","journal-title":"BMJ Open"},{"key":"R32-20250507","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J Peripher Nerv Syst."},{"key":"R33-20250507","doi-asserted-by":"crossref","first-page":"p519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"R34-20250507","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp-2020-325815","article-title":"Intravenous immunoglobulin treatment for mild Guillain-Barr\u00e9 syndrome: an international observational study","volume":"92","author":"Verboon","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:03:26Z","timestamp":1746651806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000441","relation":{},"ISSN":["1522-0443"],"issn-type":[{"type":"print","value":"1522-0443"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}